Trials / Unknown
UnknownNCT00937261
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be evaluated with PET imaging, fMRI, and neurological ratings and assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risperidone | 2mg - 8mg per day, for the duration of participation in the study |
| DRUG | Paliperidone | 6mg - 12mg per day, for the duration of participation in the study |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-07-01
- Completion
- 2011-01-01
- First posted
- 2009-07-10
- Last updated
- 2010-10-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00937261. Inclusion in this directory is not an endorsement.